넥스트바이오메디컬

389650KOSDAQ의료용 기기 제조업

51.3 / 100

Reference Date: 2026-07-24

Financial Score15.0 / 40

News Sentiment21.3 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 13.7% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

NextBioMedical is a biopharma company specializing in drug delivery systems, biocompatible medical devices, and oncology treatments. It focuses on developing pharmaceutical-medical device convergence products, particularly drug-eluting beads for liver cancer therapy and interventional radiology technologies.

Number of Employees

81people

Average Salary

45.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 20.044.0Point

PBR

6.22Industry Average 1.140.0Point

5.5x industry avg (risky)

ROE

-0.67Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

6.47Industry Average 11.655.0Point

Lower than industry avg (good)

Trend 2024~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲72.7% (1-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲79.9% (1-year basis)

ROE Trend

0.0 / 4

Detailed News Sentiment

4 totalPositive 4Neutral 0Negative 0Average Sentiment Score 85

Positive
넥스트바이오메디컬, ‘넥스피어에프’ 신규 임상 추진...‘색전 플랫.....
넥스트바이오메디컬의 새로운 임상 진행 소식으로 주가 상승 기대.
Positive
넥스트바이오메디컬, '넥스피어에프' 美 FDA 허가 준비 본격화
넥스트바이오메디컬의 주요 제품 '넥스피어에프'가 미국 FDA 허가 절차를 가속화하며 글로벌 시장 진출에 긍정적 영향을 미치고 있다.
Positive
색전술, 폐색 영구서 일시로 대세 변화...넥스트바이오 가치 더 커진다
넥스트바이오메디컬의 색전술 기술이 시장 패러다임 변화를 이끌어 회사 가치 상승에 기여할 것으로 예상됩니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (4%, downtrend)

Current 36,150Won52-week high 98,00052-week low 33,100

1-month return1.0Point

1m -13.72% (falling)

Volume trend3.0Point

Volume flat

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-25